{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:56:19Z","timestamp":1790916979289,"version":"4.1.0"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s11523-026-01248-7","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T02:23:46Z","timestamp":1785983026000},"page":"617-620","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Subcutaneous Amivantamab and Lazertinib in PALOMA-3: Efficacy, Safety, and Administration: A Vodcast"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2479-2271","authenticated-orcid":false,"given":"Danny","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"1248_CR1","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/S1470-2045(19)30504-2","volume":"20","author":"MJ Ahn","year":"2019","unstructured":"Ahn MJ, Han JY, Lee KH, et al. Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study. Lancet Oncol. 2019;20:1681\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(19)30504-2.","journal-title":"Lancet Oncol"},{"key":"1248_CR2","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1158\/1078-0432.CCR-18-2906","volume":"25","author":"J Yun","year":"2019","unstructured":"Yun J, Hong MH, Kim SY, et al. YH25448, an irreversible EGFR-TKI with potent intracranial activity in EGFR mutant non-small cell lung cancer. Clin Cancer Res. 2019;25:2575\u201387. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2906.","journal-title":"Clin Cancer Res"},{"key":"1248_CR3","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1021\/acsmedchemlett.2c00213","volume":"13","author":"DE Heppner","year":"2022","unstructured":"Heppner DE, Wittlinger F, Beyett TS, et al. Structural basis for inhibition of mutant EGFR with lazertinib (YH25448). ACS Med Chem Lett. 2022;13:1856\u201363. https:\/\/doi.org\/10.1021\/acsmedchemlett.2c00213.","journal-title":"ACS Med Chem Lett"},{"key":"1248_CR4","unstructured":"RYBREVANT FASPRO\u2122 (amivantamab and hyaluronidase-lpuj) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; 2025."},{"key":"1248_CR5","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1200\/JCO.24.01001","volume":"42","author":"NB Leighl","year":"2024","unstructured":"Leighl NB, Akamatsu H, Lim SM, et al. Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory epidermal growth factor receptor-mutated non-small cell lung cancer: primary results from the Phase III PALOMA-3 study. J Clin Oncol. 2024;42:3593\u20135. https:\/\/doi.org\/10.1200\/JCO.24.01001.","journal-title":"J Clin Oncol"},{"key":"1248_CR6","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.jtho.2025.07.117","volume":"20s","author":"BC Cho","year":"2025","unstructured":"Cho BC, Li W, Spira AI, et al. Enhanced versus standard dermatologic management with amivantamab-lazertinib in EGFR-mutated advanced NSCLC: The COCOON Global Randomized Controlled Trial. J Thorac Oncol. 2025;20s:1517\u201330. https:\/\/doi.org\/10.1016\/j.jtho.2025.07.117.","journal-title":"J Thorac Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01248-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01248-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01248-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:52:08Z","timestamp":1790916728000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01248-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":6,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1248"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01248-7","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"assertion":[{"value":"1 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D. Nguyen reports: honoraria\/advisory role: Black Diamond Therapeutics, Johnson & Johnson, Taiho Pharmaceutical; research funding: AstraZeneca, Johnson & Johnson; travel and expenses: Corcept Therapeutics, Johnson & Johnson, Taiho Pharmaceutical; stock or other interests: Johnson & Johnson, Novartis, Pfizer, Seagen, Takeda.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The PALOMA-3 study was conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Guidelines of the International Council for Harmonisation. The protocol and amendments were approved by the institutional review board at each study site.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided written informed consent for this study.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data sharing policy of Johnson & Johnson is available at\n                      \n                      . As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at\n                      \n                      .","order":5,"name":"Ethics","label":"Availability of Data and Materials","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"D. Nguyen: conceptualization; data curation; writing\u2014original draft; and writing\u2014review and editing.","order":7,"name":"Ethics","label":"Author\u2019s Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}